Thus, the methylation of ADAMTS1 proved to be positive in 87.5% of patients with stage I cancers, 77.8% of patients with stage IIA, 90% of patients with stage IIB, and 100% of patients with stage III/IV PC [5]. This evidence concerns the gene ADAMTS1 and pachyonychia congenita.